식별자 및 물리적 특성
| CAS No. | 297-90-5 |
|---|
| 분자식 | C17H23NO |
|---|
| 평균 분자량 | 257.37 g/mol |
|---|
| 단동위원소 질량 | 257.17796436 g/mol |
|---|
| SMILES | CN1CCC23CCCCC2C1Cc1ccc(O)cc13 |
|---|
| InChIKey | JAQUASYNZVUNQP-UHFFFAOYSA-N |
|---|
| PubChem CID | 3918 |
|---|
| ChEMBL | CHEMBL20803 |
|---|
| EC No. | 206-048-0 |
|---|
화학 및 물리적 성질
| XLogP | 3.1 |
|---|
| 극성 표면적 | 23.5 |
|---|
| 수소 결합 공여자 수 | 1 |
|---|
| 수소 결합 수용자 수 | 2 |
|---|
| 회전 가능 결합 수 | 0 |
|---|
| 무거운 원자 수 | 19 |
|---|
| 형식 전하 | 0 |
|---|
| 복잡도 | 357 |
|---|
| 의약품 | DEA NFLIS-Drug Category -> Narcotic AnalgesicsDEA Schedule II Controlled Substance -> Opiates |
|---|
안전 및 규제
| 규제 정보 | DEA schedule II controlled substance |
|---|
| Treatment | The specific treatment of suspected levorphanol tartrate overdosage is immediate establishment of an adequate airway and ventilation, followed (if necessary) by intravenous naloxone. The respiratory and cardiac status of the patient should be continuously monitored and appropriate supportive measures instituted, such as oxygen, intravenous fluids and/or vasopressors, if required. Physicians are reminded that the duration of levorphanol action far exceeds the duration of action of naloxone, and repeated dosing with naloxone may be required. Naloxone should be administered cautiously to persons known or suspected to be physically dependent on Levorphanol. In such cases an abrupt and complete reversal of opioid effects may precipitate an acute abstinence syndrome. If necessary to administer naloxone to the physically dependent patient, the antagonist should be administered with extreme care and by titration with smaller than usual doses of the antagonist. (L1712) |
|---|
| 건강 영향 | Medical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose. |
|---|
| 노출 경로 | Subcutaneous, Intravenous, or Intramuscular injectionOral. Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing. |
|---|
| 독성 요약 | Like other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain. |
|---|
| Signs and Symptoms | Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria. |
|---|
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
|---|
| Toxicity Data | LD50: 150 mg/kg (Oral, Rat) (A308) |
|---|
